Cerebras Faces Separate Tests: Culper's Chip-Durability Claim, Sean Lie's Form 144, and a November Earnings Date
Published on 10/29/2026 at 03:40 | Editorial boerse-global.de
Two unrelated disclosures landed on Cerebras in the space of a day, and neither one settles the central question of how durable the company's underlying business really is. Short seller Culper Research published allegations about the working lifespan of Cerebras's wafer-scale chips, according to media reports, while a Form 144 filed on the company's SEC submissions page listed a planned sale of 60,000 common shares by Sean Lie. Both items moved the narrative. Neither constitutes proof of anything.
Start with the short seller. Culper claims Cerebras's wafer-scale hardware holds up for only 1.5 to 2.5 years in real-world deployment — an assertion that, if true, would bear directly on the economics of the core product. The firm also disclosed its own short position, which gives it a financial stake in a falling share price. That doesn't make the claim false. It does mean investors should keep the thesis and the evidence in separate boxes. Media reports point to the Culper note as the trigger for yesterday's share-price decline, but a price move documents a market reaction, not a technical finding. No independent verification of the durability claim has been produced.
The insider filing carries a similar caveat. A Form 144 records an intention to sell, not a completed transaction, and nothing in it speaks to operating performance or to Lie's motives. Reading it as an earnings warning would be a stretch. The share-supply angle has nonetheless been live for a while: on October 19, Joshua Buchalter of TD Cowen cut his 12-month price target on Cerebras from $275 to $175, according to media reports, while keeping his Buy rating. His reasoning tied together two distinct risks — uncertainty over OpenAI's hardware choices for AI inference and pressure from the equity offering. The planned sale touches a theme the analyst had already flagged, but on its own it confirms neither a weakening business nor an OpenAI decision against Cerebras. A lower target with an unchanged Buy rating is a more cautious valuation, not a sell call.
Should investors sell immediately? Or is it worth buying CEREBRAS SYSTEMS INC - A?
Running alongside these concerns is a genuine piece of commercial news. Reuters reported on Tuesday that Oracle intends to offer Cerebras alongside Google chips and other Nvidia alternatives, widening its menu rather than committing to a single vendor. Cerebras and Oracle announced their own collaboration the same day: inference services on Oracle Cloud Infrastructure aimed at AI labs, enterprises and developers, with availability slated for 2027. That opens a distribution channel. It says nothing about how long the hardware lasts in service, just as an unverified durability claim doesn't invalidate the partnership. Investors who conflate the two will either over-credit the Oracle deal or over-weight the short report.
The next hard data point is scheduled. Cerebras announced on October 20 that it will report third-quarter 2026 results after the market close on November 12, 2026, followed by a conference call. That date won't adjudicate the technical allegations — financial statements and durability statements answer different questions — but it will show which claims management actually makes and what weight they can carry. For now, the Oracle channel and the Culper thesis each deserve their own assessment, and neither relieves investors of the work.
Ad
CEREBRAS SYSTEMS INC - A Stock: New Analysis - 29 October
Fresh CEREBRAS SYSTEMS INC - A information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
